<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375608</url>
  </required_header>
  <id_info>
    <org_study_id>110184</org_study_id>
    <secondary_id>11-H-0184</secondary_id>
    <nct_id>NCT01375608</nct_id>
  </id_info>
  <brief_title>Decitabine for High-Risk Sickle Cell Disease</brief_title>
  <official_title>An Extended Phase 2 Study of Decitabine in Subjects With High Risk Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  In sickle cell disease (SCD), the proteins in the red blood cells that carry oxygen do&#xD;
           not behave normally. In parts of the body where there are low levels of oxygen or where&#xD;
           oxygen is used more, the sickle hemoglobin proteins may change shape and stick together.&#xD;
           This causes the red cells to clump, which reduces blood flow. This leads to even lower&#xD;
           oxygen levels and causes damage and/or pain.&#xD;
&#xD;
        -  One way to stop the red blood cells from sticking together is to increase the levels of&#xD;
           fetal (baby or good ) hemoglobin. The good hemoglobin then takes the place of the sickle&#xD;
           hemoglobin.&#xD;
&#xD;
        -  Hydroxyurea is the only approved drug for SCD. But hydroxyurea works in only about&#xD;
           two-thirds of people with SCD. Even in those cases it sometimes stops working over time.&#xD;
&#xD;
        -  Researchers are interested in testing decitabine. The drug may help to increase fetal&#xD;
           hemoglobin levels. But it has not yet been approved to treat SCD.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To test the safety and effectiveness of decitabine in increasing fetal hemoglobin levels&#xD;
      and improving the symptoms of sickle cell disease.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - People at least 18 years of age who have sickle cell disease that has not improved after at&#xD;
      least 6 months of hydroxyurea therapy. Those who cannot take hydroxyurea because of side&#xD;
      effects may also participate.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. They will also&#xD;
           have blood and urine tests, a lung function test, and other tests as required.&#xD;
&#xD;
        -  Participants will receive decitabine injections up to twice a week for 1 year. Depending&#xD;
           on the response to treatments, the dose will remain the same or be reduced to once a&#xD;
           week.&#xD;
&#xD;
        -  Participants will be monitored with frequent blood tests and other studies as directed&#xD;
           by the study doctors.&#xD;
&#xD;
        -  After the study is completed, participants will go back to their usual sickle cell care.&#xD;
           If decitabine has improved a participant's SCD, treatment may be continued under regular&#xD;
           health coverage insurance if this can be arranged.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview: Elevated fetal hemoglobin (HbF), whether pharmacologically induced or congenital,&#xD;
      has a favorable impact on the morbidity and mortality of SCD. The agent currently used to&#xD;
      elevate HbF, hydroxyurea (HU), has limited efficacy. There are mechanistic reasons to believe&#xD;
      that the DNA methyltransferase inhibitor 5-aza-2 -deoxycytidine (decitabine) can more&#xD;
      potently increase HbF. This has been demonstrated in vivo in animals and small phase 1/2&#xD;
      studies of decitabine in SCD subjects. Decitabine at low, non-cytotoxic doses was very well&#xD;
      tolerated and very efficacious at increasing HbF and total hemoglobin (Hb) in subjects who&#xD;
      did not respond to, or were intolerant of, HU. In addition to HbF levels, major improvements&#xD;
      were noted in a range of surrogate clinical endpoints measuring red blood cell (RBC)&#xD;
      adhesion, endothelial damage, and coagulation pathway activity. Also, substantial clinical&#xD;
      improvement was seen in severely ill patients treated off-label. The primary objective herein&#xD;
      is to provide evidence and guidance for a phase III study by demonstrating the dose and&#xD;
      schedule of decitabine that when given over a 12 month period, produces sustained elevations&#xD;
      in HbF without significant toxicity. Secondary objectives examine patient reported outcome&#xD;
      measurements (PROMIS), crisis frequency, and laboratory indices that measure different&#xD;
      domains of sickle cell pathophysiology and DNA methylation. These secondary and scientific&#xD;
      measurements will be correlated with each other and examined over time to understand&#xD;
      mechanisms of disease and the mechanism of action of the study drug.&#xD;
&#xD;
      Intervention: Decitabine starting dose of 0.2 mg/kg (range, 0.05-0.3 mg/kg) 1-2x/wk x 48&#xD;
      weeks&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
      In SCD subjects at risk of early death, non-cytotoxic DNMT1 depletion using a metronomic&#xD;
      (frequent but intermittent) regimen of the nucleoside analogue decitabine directly&#xD;
      antagonizes a mechanism of gamma-globin repression, and produces sustained, clinically&#xD;
      significant HbF elevations.&#xD;
&#xD;
      Primary Objective: To measure, in high-risk SCD subjects, the effect of chronic metronomic&#xD;
      subcutaneous (SQ) decitabine administration on HbF levels. These aims are achieved through&#xD;
      the conduct of an extended, open-label, phase 2 study in subjects who remain at high risk of&#xD;
      early mortality and morbidity despite HU therapy.&#xD;
&#xD;
      Secondary Objectives: To measure, in high-risk SCD subjects, the effect of chronic metronomic&#xD;
      SQ decitabine administration on clinical and laboratory indices of safety, patient reported&#xD;
      outcome measures (PROMIS), frequency of crises, SCD pathophysiologic activity (hemolysis,&#xD;
      coagulation, platelet activation and inflammation), and molecular effects of study drug.&#xD;
&#xD;
      Criteria for Evaluation:&#xD;
&#xD;
      Primary Endpoint: the percentage change in HbF level from baseline to the average percent&#xD;
      over the final 3 months of the study period (48 weeks).&#xD;
&#xD;
      Secondary Endpoints: clinical and laboratory assessment of safety, patient reported outcomes&#xD;
      (PROMIS), frequency of crises, quantity of F cells and F cell subsets, measurements of&#xD;
      hemolysis, coagulation, platelet activation, inflammation, endothelial damage, pulmonary&#xD;
      arterial pressure, DNMT levels, global and beta-globin locus specific DNA methylation.&#xD;
&#xD;
      Study Design: This is an extended, single arm, open-label, phase II clinical trial.&#xD;
&#xD;
      Study Population: Adults with symptomatic SCD who are at high risk of early mortality despite&#xD;
      greater than or equal to 6 months of HU therapy. Specifically, they still have: HbF &lt;5&#xD;
      percent, OR 3 or more pain episodes per year requiring parenteral narcotics, OR 1 or more&#xD;
      acute chest syndrome episodes, OR hemoglobin &lt;9 g/dL and absolute reticulocyte count (ARC)&#xD;
      less than or equal to 250,000/mm(3). Subjects who meet the above criteria for high risk but&#xD;
      are unwilling or unable to tolerate HU are also eligible.&#xD;
&#xD;
      Clinical and Laboratory Evaluations:&#xD;
&#xD;
      Pre-treatment and every 2 weeks: CBC, chem 20 including LDH, and retic count&#xD;
&#xD;
      Pre-treatment and every 4 weeks: interim medical history &amp; physical exam, HbF%, and pregnancy&#xD;
      test&#xD;
&#xD;
      Pre-treatment and every 12 weeks: urinanalysis, percent F-cells &amp; percent F-reticulocytes,&#xD;
      biomarkers, scientific correlative studies of DNA methylation&#xD;
&#xD;
      Pre-treatment, 24 and 48 weeks: PROMIS, PFT, 6 minute walk, endo-PAT&#xD;
&#xD;
      Pre-treatment and 48 weeks: erythropoietin level&#xD;
&#xD;
      Follow-ups every 3-4 months between 52-54 weeks and 93-96 weeks: interim medical history &amp;&#xD;
      physical exam, CBC, reticulocyte count, HbF percent, chem 20 (including LDH), and pregnancy&#xD;
      test&#xD;
&#xD;
      Sample Size: 40 subjects&#xD;
&#xD;
      Data Analyses: The effect of decitabine on HbF levels over time will be explored using a&#xD;
      general linear mixed model from which the average percent change from baseline to the average&#xD;
      HbF level on the final 3 months of treatment will be estimated along with a 95 percent&#xD;
      confidence interval. AE and other safety measurements will be summarized by age group, dose,&#xD;
      and dose frequency at the time of AE onset. No interim analyses will be performed in this&#xD;
      study.&#xD;
&#xD;
      Human Subjects: There is a risk of neutropenia, thrombocytosis, and teratogenicity. Patients&#xD;
      must take precautions to use contraception and avoid pregnancy during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study.</measure>
    <time_frame>Final 1 month of study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Neutropenia</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>decitabine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.</description>
    <arm_group_label>decitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Subjects who meet all of the following criteria are eligible for enrollment into the study:&#xD;
&#xD;
          1. Age 18 years or older.&#xD;
&#xD;
          2. Written, informed consent provided by the subject before study entry.&#xD;
&#xD;
          3. Confirmed SCD (SS, S-beta (0)-thalassemia, or SC on hemoglobin electrophoresis),&#xD;
&#xD;
          4. Symptomatic SCD while on 6 months of HU OR symptomatic SCD and intolerant of HU&#xD;
             (unable or unwilling to tolerate HU due to hematological or other toxicities).&#xD;
             Symptomatic SCD is defined as having one of following:&#xD;
&#xD;
               -  HbF &lt;5 percent, OR&#xD;
&#xD;
               -  3 or more pain episodes per year requiring parenteral narcotics, OR&#xD;
&#xD;
               -  1 or more acute chest syndrome episodes, OR&#xD;
&#xD;
               -  Hemoglobin &lt;9 degree g/dL and ARC less than or equal to 250,000/mm(3),&#xD;
&#xD;
          5. Subject is in his/her steady state and not amidst any acute complication due to SCD.&#xD;
&#xD;
          6. Willing to use 2 forms of contraception. Some acceptable combinations include male&#xD;
             partner using condoms and female partner using oral contraceptives, male partner using&#xD;
             condoms and female partner who had bilateral oophorectomy, male partner who had a&#xD;
             vasectomy and female partner using injectable contraceptives (e.g. Depo Provera).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Since the protocol targets an at risk population, and the tolerability and potential&#xD;
        benefits of this approach have been suggested in off-label treatment of seriously ill SCD&#xD;
        patients, the exclusion criteria are not overly stringent and are primarily directed at&#xD;
        avoiding teratogenic risks.&#xD;
&#xD;
        Subjects who meet any of the following criteria are disqualified from enrollment in the&#xD;
        study:&#xD;
&#xD;
          1. Inability to give informed consent.&#xD;
&#xD;
          2. Experienced severe sepsis or septic shock within the previous 12 weeks.&#xD;
&#xD;
          3. Last HU or erythropoietin dose obtained within the previous 4 weeks. Renal replacement&#xD;
             doses of erythropoietin is allowed as decitabine would not be expected to exert a red&#xD;
             cell and/or HbF response when there is no endogenous erythropoietin production.&#xD;
&#xD;
          4. Participant is on chronic transfusion therapy (e.g., for history of TIA or stroke) and&#xD;
             medically contraindicated to discontinue transfusions.&#xD;
&#xD;
          5. Currently pregnant or breast-feeding.&#xD;
&#xD;
          6. Sexually active female of childbearing potential (all females except those who are&#xD;
             menopausal [appropriate age and no period for more than 12 months] or have had a&#xD;
             hysterectomy and/or bilateral oophorectomy) who is unwilling to use at least 2&#xD;
             acceptable methods of contraception as determined by the investigators. The use of a&#xD;
             condom by a male partner would be considered one acceptable method of contraception.&#xD;
&#xD;
          7. Sexually active male whose partner is of child-bearing potential and who is unwilling&#xD;
             to use at least 2 acceptable methods of contraception as determined by the&#xD;
             investigators during treatment and for 8 weeks after the last dose of decitabine.&#xD;
&#xD;
          8. Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such&#xD;
             severity that death within 24 weeks is likely.&#xD;
&#xD;
          9. Other experimental or investigational drug therapy in the past 28 days.&#xD;
&#xD;
         10. Inability to bring ANC above 2 x 10(9) cells/L or platelet count less than 1,000 x&#xD;
             10(9) cells/L.&#xD;
&#xD;
        For female participants: Not having heterosexual sexual contact starting 4 weeks before&#xD;
        beginning to take decitabine and continuing until 4 weeks after the last dose of decitabine&#xD;
        OR using TWO methods of birth control. One birth control method must be highly effective,&#xD;
        such as an Intrauterine Device (IUD), birth control pills, Depo-Provera&#xD;
        (medroxyprogesterone acetate) injections, or tying of the fallopian tubes. The other&#xD;
        additional effective method of birth control can be use of a diaphragm or a condom by the&#xD;
        male partner. Birth control should begin at the screening visit and continue until 4 weeks&#xD;
        after the last dose of decitabine. These steps must be taken even if the patient has a&#xD;
        history of infertility, unless the patient has had a hysterectomy or has not had periods&#xD;
        for at least 24 months.&#xD;
&#xD;
        For male participants: during decitabine treatment and 8 weeks after last dose of drug, a&#xD;
        condom must be used when engaging in any sexual contact with a woman of child-bearing age,&#xD;
        even in patients who have had a successful vasectomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew M Hsieh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-H-0184.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>WATSON J. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci. 1948 Apr;215(4):419-23.</citation>
    <PMID>18107723</PMID>
  </reference>
  <reference>
    <citation>CONLEY CL, WEATHERALL DJ, RICHARDSON SN, SHEPARD MK, CHARACHE S. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood. 1963 Mar;21:261-81.</citation>
    <PMID>14022587</PMID>
  </reference>
  <reference>
    <citation>Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med. 1978 Jan;88(1):1-6.</citation>
    <PMID>619731</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Hemaglobin</keyword>
  <keyword>Coagulation Disorders</keyword>
  <keyword>Thrombocytosis</keyword>
  <keyword>Red Blood Cells</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous Decitabine in Sickle Cell Disease</title>
          <description>decitabine (starting dose of 0.20 mg/kg, 2 days per week) to induce fetal hemoglobin (HbF) in patients with sickle cell anemia who are refractory to or intolerant of hydroxyurea</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous Decitabine in Sickle Cell Disease</title>
          <description>decitabine (starting dose of 0.20 mg/kg, 2 days per week) to induce fetal hemoglobin (HbF) in patients with sickle cell anemia who are refractory to or intolerant of hydroxyurea</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>total hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.14" lower_limit="4.9" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fetal hemoglobin</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" lower_limit="1" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study.</title>
        <time_frame>Final 1 month of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Decitabine in Sickle Cell Disease</title>
            <description>decitabine (starting dose of 0.20 mg/kg, 2 days per week) to induce fetal hemoglobin (HbF) in patients with sickle cell anemia who are refractory to or intolerant of hydroxyurea</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>total Hgb increase by &gt;1g/dL AND HbF by &gt;10%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>total hgb increase by &gt;1 g/dL OR HbF by 10%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>total hgb increase by &lt;1 g/dL OR HbF by &lt;10%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>January 2012 to December 2015</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subcutaneous Decitabine in Sickle Cell Disease</title>
          <description>decitabine (starting dose of 0.20 mg/kg, 2 days per week) to induce fetal hemoglobin (HbF) in patients with sickle cell anemia who are refractory to or intolerant of hydroxyurea</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>non sickle related SAE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle related</sub_title>
                <counts group_id="E1" events="30" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ENT</sub_title>
                <description>metallic taste, hearing changes, jaw pain, dry mouth</description>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disturbances</sub_title>
                <description>Nausea, vomiting, diarrhea, changes in appetite</description>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>temporary musckle weakness with injection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>related to subcutaneous injection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Matthew Hsieh</name_or_title>
      <organization>NIH, NHLBI, MCHB</organization>
      <phone>301-402-7687</phone>
      <email>matthewhs@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

